Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity

Yuanyuan Xiao, Manish Muhuri, Shaoyong Li, Wanru Qin, Guangchao Xu, Li Luo, Jia Li, Alexander J. Letizia, Sean K. Wang, Ying Kai Chan, Chunmei Wang, Sebastian P. Fuchs, Dan Wang, Qin Su, M. Abu Nahid, George M. Church, Michael Farzan, Li Yang, Yuquan Wei, Ronald Charles Desrosiers & 3 others Christian Mueller, Phillip W.L. Tai, Guangping Gao

Research output: Contribution to journalArticle

Abstract

Recombinant adeno-associated virus–mediated (rAAV-mediated) gene delivery can efficiently target muscle tissues to serve as “biofactories” for secreted proteins in prophylactic and therapeutic scenarios. Nevertheless, efficient rAAV-mediated gene delivery is often limited by host immune responses against the transgene product. The development of strategies to prevent antitransgene immunity is therefore crucial. The use of endogenous microRNA-mediated (miRNA-mediated) regulation to detarget transgene expression from antigen-presenting cells (APCs) has shown promise for reducing immunogenicity. However, the mechanisms underlying miRNA-mediated modulation of antitransgene immunity by APC detargeting are not fully understood. Using the highly immunogenic ovalbumin (OVA) protein as a proxy for foreign antigens, we show that rAAV vectors containing miR142-binding sites efficiently repress costimulatory signals in DCs, significantly blunt the cytotoxic T cell response, allow for sustained transgene expression in skeletal myoblasts, and attenuate clearance of transduced muscle cells in mice. Furthermore, the blunting of humoral immunity against circulating OVA correlates with detargeting of OVA expression from APCs. This demonstrates that incorporating APC-specific miRNA-binding sites into rAAV vectors provides an effective strategy for reducing transgene-specific immune response. This approach holds promise for clinical applications where the safe and efficient delivery of a prophylactic or therapeutic protein is desired.

Original languageEnglish (US)
Article numbere99052.
JournalJCI Insight
Volume4
Issue number13
DOIs
StatePublished - Jul 11 2019

Fingerprint

Ovalbumin
Antigen-Presenting Cells
Humoral Immunity
Transgenes
Cellular Immunity
MicroRNAs
Immunity
Binding Sites
Skeletal Myoblasts
Proteins
Proxy
Muscle Cells
Genes
T-Lymphocytes
Antigens
Muscles
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. / Xiao, Yuanyuan; Muhuri, Manish; Li, Shaoyong; Qin, Wanru; Xu, Guangchao; Luo, Li; Li, Jia; Letizia, Alexander J.; Wang, Sean K.; Chan, Ying Kai; Wang, Chunmei; Fuchs, Sebastian P.; Wang, Dan; Su, Qin; Abu Nahid, M.; Church, George M.; Farzan, Michael; Yang, Li; Wei, Yuquan; Desrosiers, Ronald Charles; Mueller, Christian; Tai, Phillip W.L.; Gao, Guangping.

In: JCI Insight, Vol. 4, No. 13, e99052., 11.07.2019.

Research output: Contribution to journalArticle

Xiao, Y, Muhuri, M, Li, S, Qin, W, Xu, G, Luo, L, Li, J, Letizia, AJ, Wang, SK, Chan, YK, Wang, C, Fuchs, SP, Wang, D, Su, Q, Abu Nahid, M, Church, GM, Farzan, M, Yang, L, Wei, Y, Desrosiers, RC, Mueller, C, Tai, PWL & Gao, G 2019, 'Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity', JCI Insight, vol. 4, no. 13, e99052.. https://doi.org/10.1172/jci.insight.99052
Xiao, Yuanyuan ; Muhuri, Manish ; Li, Shaoyong ; Qin, Wanru ; Xu, Guangchao ; Luo, Li ; Li, Jia ; Letizia, Alexander J. ; Wang, Sean K. ; Chan, Ying Kai ; Wang, Chunmei ; Fuchs, Sebastian P. ; Wang, Dan ; Su, Qin ; Abu Nahid, M. ; Church, George M. ; Farzan, Michael ; Yang, Li ; Wei, Yuquan ; Desrosiers, Ronald Charles ; Mueller, Christian ; Tai, Phillip W.L. ; Gao, Guangping. / Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. In: JCI Insight. 2019 ; Vol. 4, No. 13.
@article{b5feed7aaeee44adb64429d41a0a50b3,
title = "Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity",
abstract = "Recombinant adeno-associated virus–mediated (rAAV-mediated) gene delivery can efficiently target muscle tissues to serve as “biofactories” for secreted proteins in prophylactic and therapeutic scenarios. Nevertheless, efficient rAAV-mediated gene delivery is often limited by host immune responses against the transgene product. The development of strategies to prevent antitransgene immunity is therefore crucial. The use of endogenous microRNA-mediated (miRNA-mediated) regulation to detarget transgene expression from antigen-presenting cells (APCs) has shown promise for reducing immunogenicity. However, the mechanisms underlying miRNA-mediated modulation of antitransgene immunity by APC detargeting are not fully understood. Using the highly immunogenic ovalbumin (OVA) protein as a proxy for foreign antigens, we show that rAAV vectors containing miR142-binding sites efficiently repress costimulatory signals in DCs, significantly blunt the cytotoxic T cell response, allow for sustained transgene expression in skeletal myoblasts, and attenuate clearance of transduced muscle cells in mice. Furthermore, the blunting of humoral immunity against circulating OVA correlates with detargeting of OVA expression from APCs. This demonstrates that incorporating APC-specific miRNA-binding sites into rAAV vectors provides an effective strategy for reducing transgene-specific immune response. This approach holds promise for clinical applications where the safe and efficient delivery of a prophylactic or therapeutic protein is desired.",
author = "Yuanyuan Xiao and Manish Muhuri and Shaoyong Li and Wanru Qin and Guangchao Xu and Li Luo and Jia Li and Letizia, {Alexander J.} and Wang, {Sean K.} and Chan, {Ying Kai} and Chunmei Wang and Fuchs, {Sebastian P.} and Dan Wang and Qin Su and {Abu Nahid}, M. and Church, {George M.} and Michael Farzan and Li Yang and Yuquan Wei and Desrosiers, {Ronald Charles} and Christian Mueller and Tai, {Phillip W.L.} and Guangping Gao",
year = "2019",
month = "7",
day = "11",
doi = "10.1172/jci.insight.99052",
language = "English (US)",
volume = "4",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "13",

}

TY - JOUR

T1 - Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity

AU - Xiao, Yuanyuan

AU - Muhuri, Manish

AU - Li, Shaoyong

AU - Qin, Wanru

AU - Xu, Guangchao

AU - Luo, Li

AU - Li, Jia

AU - Letizia, Alexander J.

AU - Wang, Sean K.

AU - Chan, Ying Kai

AU - Wang, Chunmei

AU - Fuchs, Sebastian P.

AU - Wang, Dan

AU - Su, Qin

AU - Abu Nahid, M.

AU - Church, George M.

AU - Farzan, Michael

AU - Yang, Li

AU - Wei, Yuquan

AU - Desrosiers, Ronald Charles

AU - Mueller, Christian

AU - Tai, Phillip W.L.

AU - Gao, Guangping

PY - 2019/7/11

Y1 - 2019/7/11

N2 - Recombinant adeno-associated virus–mediated (rAAV-mediated) gene delivery can efficiently target muscle tissues to serve as “biofactories” for secreted proteins in prophylactic and therapeutic scenarios. Nevertheless, efficient rAAV-mediated gene delivery is often limited by host immune responses against the transgene product. The development of strategies to prevent antitransgene immunity is therefore crucial. The use of endogenous microRNA-mediated (miRNA-mediated) regulation to detarget transgene expression from antigen-presenting cells (APCs) has shown promise for reducing immunogenicity. However, the mechanisms underlying miRNA-mediated modulation of antitransgene immunity by APC detargeting are not fully understood. Using the highly immunogenic ovalbumin (OVA) protein as a proxy for foreign antigens, we show that rAAV vectors containing miR142-binding sites efficiently repress costimulatory signals in DCs, significantly blunt the cytotoxic T cell response, allow for sustained transgene expression in skeletal myoblasts, and attenuate clearance of transduced muscle cells in mice. Furthermore, the blunting of humoral immunity against circulating OVA correlates with detargeting of OVA expression from APCs. This demonstrates that incorporating APC-specific miRNA-binding sites into rAAV vectors provides an effective strategy for reducing transgene-specific immune response. This approach holds promise for clinical applications where the safe and efficient delivery of a prophylactic or therapeutic protein is desired.

AB - Recombinant adeno-associated virus–mediated (rAAV-mediated) gene delivery can efficiently target muscle tissues to serve as “biofactories” for secreted proteins in prophylactic and therapeutic scenarios. Nevertheless, efficient rAAV-mediated gene delivery is often limited by host immune responses against the transgene product. The development of strategies to prevent antitransgene immunity is therefore crucial. The use of endogenous microRNA-mediated (miRNA-mediated) regulation to detarget transgene expression from antigen-presenting cells (APCs) has shown promise for reducing immunogenicity. However, the mechanisms underlying miRNA-mediated modulation of antitransgene immunity by APC detargeting are not fully understood. Using the highly immunogenic ovalbumin (OVA) protein as a proxy for foreign antigens, we show that rAAV vectors containing miR142-binding sites efficiently repress costimulatory signals in DCs, significantly blunt the cytotoxic T cell response, allow for sustained transgene expression in skeletal myoblasts, and attenuate clearance of transduced muscle cells in mice. Furthermore, the blunting of humoral immunity against circulating OVA correlates with detargeting of OVA expression from APCs. This demonstrates that incorporating APC-specific miRNA-binding sites into rAAV vectors provides an effective strategy for reducing transgene-specific immune response. This approach holds promise for clinical applications where the safe and efficient delivery of a prophylactic or therapeutic protein is desired.

UR - http://www.scopus.com/inward/record.url?scp=85070658250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070658250&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.99052

DO - 10.1172/jci.insight.99052

M3 - Article

VL - 4

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 13

M1 - e99052.

ER -